Edition:
India

Evoke Pharma Inc (EVOK.OQ)

EVOK.OQ on NASDAQ Stock Exchange Capital Market

2.74USD
24 Nov 2017
Change (% chg)

$-0.03 (-1.08%)
Prev Close
$2.77
Open
$2.79
Day's High
$2.79
Day's Low
$2.71
Volume
4,232
Avg. Vol
43,037
52-wk High
$4.54
52-wk Low
$1.43

Latest Key Developments (Source: Significant Developments)

Evoke Pharma reports Q3 loss per share $0.34
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Evoke Pharma Inc ::Evoke Pharma reports third quarter 2017 results and highlights.Q3 loss per share $0.34.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma signs commercial agreement with Thermo Fisher Scientific
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Evoke Pharma Inc ::Signs commercial agreement with Thermo Fisher Scientific.Announced selection of Patheon division of Thermo Fisher Scientific as commercial manufacturing partner for Gimoti​.Under five-year agreement, Thermo Fisher will manufacture Gimoti for Evoke's potential commercial efforts​.  Full Article

Evoke Pharma reports positive topline results from comparative exposure pharmacokinetic study for gimoti
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Evoke Pharma Inc ::Evoke Pharma announces positive topline results from comparative exposure pharmacokinetic study for gimoti™.Evoke Pharma- co will submit a 505(b)(2) NDA with a selected gimoti dose to the U.S. FDA in Q1 of 2018​.Evoke Pharma Inc- ‍relative to safety, all gimoti doses were well‑tolerated.  Full Article

Evoke Pharma announces proposed public offering of common stock
Thursday, 16 Feb 2017 

Evoke Pharma Inc : Evoke Pharma announces proposed public offering of common stock . Evoke Pharma Inc says intends to offer and sell shares of its common stock in a "firm commitment" underwritten public offering .Evoke Pharma - Intends to use net proceeds from offering to fund clinical development, pre-approval and pre-commercialization activities for Gimoti.  Full Article

FDA exempts Evoke from requirement for human factor validation study
Wednesday, 15 Feb 2017 

Evoke Pharma Inc : FDA exempts Evoke from requirement for human factor validation study . Evoke Pharma Inc- received a letter from FDA exempting Gimoti™ from a human factors validation study requirement prior to submission of NDA . Evoke Pharma Inc- In their written response, FDA determined that an HF validation study is not needed at this time for Gimoti .Evoke Pharma Inc- Intend to pursue an NDA submission by end of year for Gimoti.  Full Article

Evoke Pharma Q2 loss per share $0.41
Tuesday, 16 Aug 2016 

Evoke Pharma Inc : Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.41.  Full Article

Evoke Pharma Q2 shr loss $0.41
Tuesday, 16 Aug 2016 

Evoke Pharma Inc : Evoke pharma reports second quarter 2016 results . Q2 shr loss $0.41 . Q2 shr view $-0.43 -- thomson reuters i/b/e/s .Evoke Pharma says "we will continue to work with fda to pursue a path to approval of gimoti".  Full Article

Evoke Pharma announces $10 million registered direct offering
Saturday, 30 Jul 2016 

Evoke Pharma Inc : Evoke Pharma announces $10 million registered direct offering priced at-the-market .Says will issue common stock at a purchase price of $3.0825 per share.  Full Article

Empery Asset Management LP reports 6.65 pct passive stake in Evoke Pharma
Friday, 29 Jul 2016 

Evoke Pharma Inc :Empery Asset Management LP reports 6.65 percent passive stake in Evoke Pharma Inc as of July 19 - Sec filing.  Full Article

Evoke Pharma provides update on proposed name for lead drug
Tuesday, 26 Jul 2016 

Evoke Pharma: Receives conditional FDA acceptance of proposed brand name for Evk-001 .Request for proprietary name review for gimoti will be included if and when evoke submits a nda for product candidate.  Full Article

BRIEF-Evoke Pharma reports Q3 loss per share $0.34

* Evoke Pharma reports third quarter 2017 results and highlights